ACRS Projected Dividend Yield
Aclaris Therapeutics Inc ( NASDAQ : ACRS )Aclaris Therapeutics is a biopharmaceutical company that develops drug candidates for immuno-inflammatory diseases. Co.'s pipeline of drug candidates includes Zunsemetinib, which is for the indication of rheumatoid arthritis (moderate to severe), psoriatic arthritis (moderate to severe), and hidradenitis suppurativa (moderate to severe); ATI-1777, which is for the indication of atopic dermatitis (moderate to severe); ATI-2138, which is for the indication of T cell-mediated autoimmune diseases; Gut-Biased Program, which is for the indication of inflammatory bowel disease; and ATI-2231, which is for the indication of metastatic breast cancer and pancreatic cancer. 20 YEAR PERFORMANCE RESULTS |
ACRS Dividend History Detail ACRS Dividend News ACRS Competitors News |
Year | Declaration Date | Ex-Dividend Date | Record Date | Payable Date | Dividend $ Amount |
Total: | 0.0000 |